Novogene Europe has expanded its single-cell RNA sequencing capability at its Cambridge Omics Centre.
“Single-cell sequencing is helping researchers study complex biological systems with a level of detail that is difficult to achieve using bulk approaches alone,” said Novogene Europe VP Tingting Zhou.
“By expanding access to single-cell sequencing workflows through our Cambridge Omics Centre, we are strengthening local support for UK researchers working across areas such as oncology, immunology, neuroscience, developmental biology and translational research.
Novogene Europe’s Cambridge service initially focuses on 3′ gene expression using cells or nuclei. These are supported by GEM-X chemistry, high-throughput Illumina sequencing and Novogene Europe’s bioinformatics expertise.
The service includes sample processing, quality control, library preparation, sequencing and comprehensive bioinformatics analysis, supporting research across oncology, immunology, neuroscience, stem cell biology, developmental biology and translational research, as well as biomarker and drug discovery.
By profiling gene expression at single-cell or single-nucleus resolution, researchers can explore cellular heterogeneity, identify rare populations and investigate how different cell types and states contribute to biological function.
This expansion follows the launch of Novogene Europe’s untargeted metabolomics service at its Cambridge Omis Centre.
